Genprex Partners With Roche Diagnostics on NSCLC Biomarker Assay Validation Studies
GNPX•Collaboration on NSCLC biomarker validation
- Genprex entered a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer trials.
- Work will focus on TROP2 scoring using Roche’s validated TROP2 antibody to align testing with Roche’s NSCLC diagnostic approach.
- Genprex cited prior data linking TROP2 H-scores above 100 and PTEN H-scores below 100 to longer progression-free survival in NSCLC.
- Validation studies are targeted for completion by end-2026, with potential integration into Genprex’s NSCLC clinical program thereafter.
Related News
Mesa Labs updates financial calendar with quarterly results release, inaugural earnings call
MLAB•
Evercore hires Citi veteran Dylan Tornay as senior managing director in equity capital markets
EVR•
